Antibody-drug conjugates (ADCs) are a rapidly emerging class of therapeutic agents that combine the target specificity of a monoclonal antibody (mAb) with the lethality of cytotoxic cellular poison. With ongoing advancements in drug engineering and fresh biologic insight into mechanisms of drug action, the ADC field is still early in its evolution but represents an exciting opportunity in the fight against cancer. In this infographic, we explore their importance as an advancing treatment and how manufacturing is revolutionizing the treatment of solid tumors. Click below to find out more.
Fill in your details to be added to our mailing list and receive our latest updates.